Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

NCT05052372 is registered in ClinicalTrials.gov with xCures as lead sponsor.

NCT NCT05052372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05052372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Lead sponsor
xCures
Phase
Observational
Overall status
Terminated
Start date
November 21, 2021
Completion date
December 20, 2022
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, bladder urothelial carcinoma, fgfr mutation, fgfr2 amplification, fgfr2 gene mutation, fgfr3 gene mutation, locally advanced urothelial carcinoma, metastatic urothelial carcinoma, platinum-resistant urothelial carcinoma, refractory bladder carcinoma, refractory bladder urothelial carcinoma, transitional cell carcinoma, urothelial carcinoma